Depletion of latent HIV-1 infection in vivo: a proof-of-concept study - Wikidata - wikimedia - TriplyDB

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

http://www.wikidata.org/entity/Q28111910

about

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection Molecular and therapeutic potential and toxicity of valproic acid Transcriptional repression of human immunodeficiency virus type 1 by AP-4 Valproic acid and HIV-1 latency: beyond the sound bite.Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid The many roles of histone deacetylases in development and physiology: implications for disease and therapy Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic Review of the twelfth West Coast Retrovirus Meeting Review of "the Twelfth West Coast Retrovirus Meeting" and "the Twenty-third Annual Symposium on Nonhuman Primate Models for AIDS".Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis Impact of Chromatin on HIV Replication The macrophage: a therapeutic target in HIV-1 infection HIV-1 functional cure: will the dream come true?Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers HIV and the chemokine system: 10 years later.Attacking pathogens through their hosts Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents A historical sketch of the discovery and development of HIV-1 integrase inhibitors Viral and latent reservoir persistence in HIV-1-infected patients on therapy Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner Activation of latent HIV using drug-loaded nanoparticles Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques Treatment of HTLV-I-Associated Myelopathy / Tropical Spastic Paraparesis: Towards Rational Targeted Therapy HIV/AIDS epidemiology, pathogenesis, prevention, and treatment Developments in HIV-1 immunotherapy and therapeutic vaccination.Therapy for persistent HIV.Controlling the HIV/AIDS epidemic: current status and global challenges Prospects for treatment of latent HIV."Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells.Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.

P2860

Q21142645-DEE7B781-2E94-466D-BF71-5610FC3C3E89 Q21296867-91E8ADCC-694C-400E-B725-5E6E5BD9EB87 Q24307916-1A2E7BD0-2EFE-49D7-81C9-C09706453611 Q24530234-86ED609B-3676-4C27-8FC7-DF9AB954EABF Q24548940-9F5C7AD8-04DE-406E-99FE-05F769860C71 Q24596282-DA396A7C-A670-49B9-917D-B17841716621 Q24628821-7345A15A-F0DD-4BF7-816D-0C051DBBA350 Q24644201-0A6E96DF-7661-424E-90F3-A981DCA92148 Q24655011-7379C7F1-AC0C-4B62-A4F3-0BBA1DF5ABD2 Q24812436-BBFEE027-CBBD-4007-B41E-D3442C94FFBC Q25256613-F33DBF0E-35D4-452B-AC9D-C3C4E51E1F34 Q26746099-7B8F4A43-AFFC-42FB-BBF6-4F029FBDD814 Q26782046-CC5642A4-C151-4A5F-9483-21ECE55B1439 Q26823236-4BA31568-569B-45DA-ABA5-872930BA5449 Q26865803-13693C3D-7E59-4948-AE4F-3820C2E8B2B0 Q27010594-13108D0E-5846-4D81-9B73-F4A71F50B46A Q27312050-2BE5D6EA-94FA-4C93-9BF6-A36C0C02DD3D Q27473020-D47B75EB-9D49-4F4E-9FD7-6B43C57F506E Q27473132-CBF8415D-F480-4B30-A300-7E6E52F2D5E7 Q28077662-BECFB7FC-4B7A-45ED-B77D-3E33D1AD3B7E Q28079455-254F284F-9464-4D15-BFC1-4A7E4B538103 Q28274166-1417CCC6-CA74-408A-9CC1-EE341B6187BB Q28469057-1C5B0D6F-1021-4AF3-8CE4-1E1C1EF40E87 Q28469068-52C51F3D-667C-4EF3-8EB9-94CF8305349D Q28474468-949D1DEA-AD86-4EBA-8A4C-A16129B42F35 Q28477657-0A7A2AB9-177E-4A7D-B87B-97EB8BFA12EC Q28540858-C5C025E2-7BF2-49D3-A5B9-6B34B34DFE33 Q28972318-48534152-5210-4ECA-BE32-6AA6ABD6132A Q30356074-43F33846-F5C6-4D92-879D-CBA4B5324147 Q30364312-5657C0FA-59EA-437C-B7F3-01A23AC01E8B Q30386370-53771494-EFC0-424E-A5A4-2E06096011BC Q30420558-E510DE9C-268D-48C3-8B13-A7DF340824D5 Q30424413-C67C95EA-1710-4E37-AEBD-67DF29E80F91 Q30488246-8CAB4864-DD8C-4C18-8B56-EA0CCFEF3F5C Q30835037-5EB9DF3F-7425-427E-95CB-A6B8BF94DC67 Q33250088-756AD66D-7F25-4C81-8B59-62E71C2E18A9 Q33265632-C55E0A88-905B-4E27-8C21-794541F56CC6 Q33313038-B412A799-D2D9-4DCC-B518-F3A8C8257A72 Q33373073-BC1DB3AD-30A0-4CD6-9D94-09A8CDD94C2A Q33425135-64C3DDBD-1C41-427F-86C5-7A593DF3B2FA

P2860

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

http://www.wikidata.org/entity/Q28111910

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@ast

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@en

type

label

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@ast

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@en

prefLabel

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@ast

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@en

P1433

Q28111910-AD927C50-3E35-4C45-AAA2-2911DD32F890

P1476

Q28111910-3CE14810-40E2-4175-A7F3-139F99ED312C

P2093

Q28111910-13FF33DD-0D6D-42A0-BCDE-E1F08312037E

Q28111910-39B94A31-4454-493E-BDE9-4031111B5763

Q28111910-533D4D92-7DF3-4883-BF16-815EE0FEC20E

Q28111910-610449B8-2407-440C-8360-96E4F4430700

Q28111910-630CFB7E-D502-4A3A-9191-AAA6E2A7DE71

Q28111910-887D4106-7527-494E-BA0E-BCDE9C778580

Q28111910-A79025F6-5E27-46CF-BE86-61988B0417F6

Q28111910-B5354920-E3AF-40B4-B986-064598AE31AB

Q28111910-BC990133-39CF-4424-8DD9-3481C5C5CF52

Q28111910-F49F6B63-1B9B-4AF0-82F5-D420E22210CD

P2860

Q28111910-00393F2A-8660-4401-8110-951B13FF9FAC

Q28111910-00B04D74-C6FE-48AB-9AAD-9AFED688F451

Q28111910-07EDFE63-8BEC-44CD-AD18-6BDC61BFCC2B

Q28111910-0976BDD4-F1E3-420D-857A-190BA05AC9A6

Q28111910-2384E8AB-0F8C-4705-8D32-0280D24A90D6

Q28111910-24A4D405-1B63-4A8C-B4FB-9CAB17A03C01

Q28111910-26166147-E930-43BA-89FC-B070C89DF058

Q28111910-29F6F4D5-1329-4369-8164-4B9608809458

Q28111910-2B94391C-FC09-4998-8D03-A161CCFEA96A

Q28111910-345CF8C3-84C1-4B6F-B88B-57E1B204E661

P304

Q28111910-74737514-C4CC-4280-9BF4-438C82EDA8C4

P31

Q28111910-CFBC84CB-D710-40E6-9229-D26428C9A2CE

P3181

Q28111910-EF25E68E-D9D4-48F9-BCCA-5C7A1319AA77

P356

Q28111910-2F02D9B7-D5CA-4130-8023-9B41D7D6DEA8

P407

Q28111910-30A6A515-037D-46B1-BAB3-70B1C60CED6E

P433

Q28111910-42154FE8-350F-458E-8F26-937FCC75EC2C

P478

Q28111910-7E4B607A-CC74-494D-82ED-07417E0C0964

P50

Q28111910-28D299C3-E0E3-434D-BD74-B7B0BA6DA00F

Q28111910-BE7CE5BB-B678-47EE-A930-74EE615A7633

P577

Q28111910-8F344E60-8FCB-4FE1-AE61-4F6C3F0DF23C

P698

Q28111910-19FDAD4B-EFB5-43E8-8E95-61F92A17F2DC

P932

Q28111910-2AFCE79B-C33C-4A51-A810-C170BD38C291

P3181

P356

S0140-6736(05)67098-5

P1433

P1476

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

@en

P2093

Alan L Landay

http://www.w3.org/2001/XMLSchema#string

Ann Wiegand

http://www.w3.org/2001/XMLSchema#string

Celsa A Spina

http://www.w3.org/2001/XMLSchema#string

Cheryl Jennings

http://www.w3.org/2001/XMLSchema#string

Douglas D Richman

http://www.w3.org/2001/XMLSchema#string

Ginger Lehrman

http://www.w3.org/2001/XMLSchema#string

John M Coffin

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Robert W Coombs

http://www.w3.org/2001/XMLSchema#string

Ronald J Bosch

http://www.w3.org/2001/XMLSchema#string

P2860

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat

Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production

Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF

Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

P304

549-555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

759078

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(05)67098-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

9485

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P50

David M. Margolis

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16099290

http://www.w3.org/2001/XMLSchema#string

P932

1894952

http://www.w3.org/2001/XMLSchema#string